Compare D R Horton Inc (DHI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs TransMedics Group Inc — how do they compare? D R Horton Inc trades at $134.45 (market cap $37.99B), while TransMedics Group Inc trades at $77.65 (market cap $2.74B). The key difference: D R Horton Inc is far larger — about 13.9× TransMedics Group Inc's market cap, and D R Horton Inc pays a 1.33% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and TransMedics Group Inc for 24 Days on average.
| DHI | TMDX | |
|---|---|---|
Market Cap | $37.99B | $2.74B |
Volume | 2,974,460 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $150.42 |
52-Week Low | $132.53 | $61.99 |
Typical Hold Time | 46 Days | 24 Days |
Enterprise Value | $43.09B | $3.13B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $134.49, down 0.91% on the day amid broader housing sector weakness. The stock shows bearish technical signals with resistance at $137 and support at $133. Fundamentally, the company maintains solid profitability with 9.15% net margin and 12.75% ROE, though revenue declined to $34.25B in 2025. Recent earnings beats and a $0.45 dividend declaration provide some positive catalysts despite macroeconomic headwinds affecting homebuilders.
DHI presents a mixed outlook with attractive valuation (P/E 12.95) and strong analyst support (47% buy ratings, $156.57 target) offset by housing market risks. Rising mortgage rates and inflation concerns create near-term pressure, but the company's consistent earnings performance and buyback capacity offer long-term value. Investors should weigh the discounted valuation against sector-specific macroeconomic challenges.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
